Baxter International Inc.

Baxter International Inc.

BAXNYSE / NASDAQHealthcareMid cap

$25.39$0.00 (0.0%)

Last close · Data as of Nov 20, 2026

Market cap
$10.0B
P/E
-10.4x
EV / EBITDA
23.2x
Revenue
$11.2B
Net margin
-8.5%
ROCE
1.0%

+45.8% over the last year

Baxter International Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+3.6%
3M
-3.9%
6M
+35.3%
1Y
+45.8%
5Y
-68.0%

52-week range

Day change $0.00 (0.0%) from $25 to $25 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BAX, bought on each weekday since 2021.

News & filings

What Baxter International filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 957 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 2.31 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.

Read moreShow less

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Sector
Healthcare
Shares outstanding
514.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$10.0B
P/E
-10.4x
P/B
1.6x
EV / EBITDA
23.2x
EV / Sales
1.6x
P/S
0.9x
52-week high
$28.35
52-week low
$15.80

Profitability

Operating margin
1.6%
Net margin
-8.5%
EBITDA margin
6.8%
ROE
-15.6%
ROCE
1.0%
ROA
-4.8%
Asset turnover
0.56

Growth

Revenue
$11.2B
Revenue growth, 1Y
5.7%
Revenue CAGR, 3Y
3.8%
Net profit growth, 1Y
47.5%
Free cash flow
$323.0M

Solvency

Current ratio
2.31
Debt / Equity
1.60
Debt / Assets
0.49
CFO / Net profit
-0.88
Cash / Market cap
19.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$11.2B
Cost of revenue$7.9B
Gross profit$3.4B
Operating expenses$3.2B
Research and development$518.0M
Selling, general and administrative$2.9B
Operating income$177.0M
Interest and other-$682.0M
Pretax income-$505.0M
Tax and other$452.0M
Net income-$957.0M

Revenue and net profit

Revenue grew 5.7% in FY2025; net profit is the dashed line.

Baxter International Inc. revenue and net profit by fiscal year
Baxter International Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$10.1B-$2.4B
FY2023$10.4B$2.7B
FY2024$10.6B-$649.0M
FY2025$11.2B-$957.0M

Cash flows

FY2025: $845.0M from operations, $323.0M free after investment (dashed).

Baxter International Inc. operating and free cash flow by fiscal year
Baxter International Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.2B$576.0M
FY2023$1.7B$1.3B
FY2024$1.0B$559.0M
FY2025$845.0M$323.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$11.2B+5.7%1Y
EBITDA
$766.0M-31.4%1Y
Net profit
-$957.0M
Cash from operations
$845.0M-17.1%1Y
Free cash flow
$323.0M-42.2%1Y
Revenue CAGR, 3Y
3.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$11.2B$766.0M-$957.0M$323.0M-15.6%+5.7%+47.5%

Monthly returns

Month-by-month returns of BAX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$20.1B
Liabilities$14.0B
Equity$6.1B
Paid-in capital$6.4B
Retained earnings$13.7B
Treasury stock$10.9B
Minority interest-$27.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BAX highlighted.

P/E against peers

BAX has no positive P/E; the peer median is 47.4x.

Not shown (no positive earnings and no EV / Sales): Baxter International Inc., Charles River Laboratories International, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Baxter International Inc.BAXthis company$10.0B-10.4x1.6x-15.6%23.2x
Revvity, Inc.RVTY$11.4B47.4x1.6x3.3%18.2x
BrightSpring Health Services, Inc.BTSG$11.3B59.4x6.0x10.2%30.3x
Molina Healthcare, Inc.MOH$10.0B21.3x2.5x11.6%—
Krystal Biotech, Inc.KRYS$9.1B44.3x7.4x16.8%51.2x
Charles River Laboratories International, Inc.CRL$8.9B—2.8x-4.6%27.5x
Henry Schein, Inc.HSIC$8.7B21.8x2.7x12.3%12.4x
Bio-Techne CorporationTECH$8.3B113.5x4.3x3.8%39.7x
Corcept Therapeutics IncorporatedCORT$8.0B80.7x12.4x15.4%66.1x
Peer median—47.4x3.6x10.9%30.3x

Year-to-date ROI

BAX since 1 January, against earlier years.

Historical volatility

BAX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Baxter International Inc. operating margin by fiscal year
Baxter International Inc. operating margin by fiscal year
DateOperating margin
FY2022-0.3%
FY20236.8%
FY20244.1%
FY20251.6%
LineFY2025
Cost of revenueCost Of Revenue$7.9B
Gross profitGross Profit$3.4B
Operating expensesOperating Expense$3.2B
Research and developmentResearch And Development$518.0M
Other operating expensesOther Operating Expenses-$206.0M
Total expensesTotal Expenses$11.1B
Pretax incomePretax Income-$505.0M

Learn while you research

Academy chapters picked for Baxter International Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 1.60 is elevated, understand what that means for solvency.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →